Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome

References

• Gartrell BA, Saad F. Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol. 2014;11(6):335–345. doi:10.1038/nrclinonc.2014.7024821212
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822. doi:10.1016/S0140-6736(10)62344-621353695
   PubMed Web of Science ®Google Scholar
• Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378(7):645–657. doi:10.1056/NEJMra170169529412780
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223. doi:10.1056/NEJMoa121375523863050
   PubMed Web of Science ®Google Scholar
• Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(20 Pt 2):6250s–6257s. doi:10.1158/1078-0432.CCR-06-084117062709
   PubMed Web of Science ®Google Scholar
• Suominen MI, Fagerlund KM, Rissanen JP, et al. Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res. 2017;23(15):4335–4346. doi:10.1158/1078-0432.CCR-16-295528364014
   PubMed Web of Science ®Google Scholar
• Templeton AJ, Vera-Badillo FE, Wang L, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol. 2013;24(12):2972–2977. doi:10.1093/annonc/mdt39724126362
   PubMed Web of Science ®Google Scholar
• Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.1714502
   PubMedGoogle Scholar
• Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306–1316. doi:10.1016/S1470-2045(16)30173-527473888
   PubMed Web of Science ®Google Scholar
• Allison PDSAUtSSAPGC, NC: SAS Institute Inc. Second edition; 282–283.
   Google Scholar
• Selby D, Cascella A, Gardiner K, et al. A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton Symptom Assessment System. J Pain Symptom Manage. 2010;39(2):241–249. doi:10.1016/j.jpainsymman.2009.06.01019963335
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Anand A, Edenbrandt L, et al. Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(7):944–951. doi:10.1001/jamaoncol.2018.109329799999
   PubMed Web of Science ®Google Scholar
• Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival. J Nucl Med. 2015;56(8):1177–1184. doi:10.2967/jnumed.115.15862626069307
   PubMed Web of Science ®Google Scholar
• Sartor O, Coleman RE, Nilsson S, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28(5):1090–1097. doi:10.1093/annonc/mdx04428453701
   PubMed Web of Science ®Google Scholar
• Parikh S, Murray L, Kenning L, et al. Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer. Clin Oncol (R Coll Radiol). 2018;30(9):548–555. doi:10.1016/j.clon.2018.06.00429934104
   PubMed Web of Science ®Google Scholar
• Parimi S, Tsang E, Alexander A, et al. A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: factors associated with treatment completion. Can Urol Assoc J. 2017;11(10):350–355. doi:10.5489/cuaj.441529382449
   PubMed Web of Science ®Google Scholar
• Wong WW, Anderson EM, Mohammadi H, et al. Factors associated with survival following radium-223 treatment for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;15(6):e969–e975. doi:10.1016/j.clgc.2017.04.01628545997
   PubMed Web of Science ®Google Scholar
• van der Doelen MJ, Kuppen MCP, Jonker MA, et al. 223Ra therapy in patients with advanced castration-resistant prostate cancer with bone metastases: lessons from daily practice. Clin Nucl Med. 2018;43(1):9–16. doi:10.1097/RLU.000000000000190429166331
   PubMed Web of Science ®Google Scholar
• Saad F, O’Sullivan JM, Carles J, et al. Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP). J Clin Oncol. 2016;34(15):suppl_abstract_5082. doi:10.1200/JCO.2016.34.15_suppl.5082
   Google Scholar
• McKay RR, Jacobus S, Fiorillo M, et al. Radium-223 use in clinical practice and variables associated with completion of therapy. Clin Genitourin Cancer. 2017;15(2):e289–e298. doi:10.1016/j.clgc.2016.08.01527651103
   PubMedGoogle Scholar
• Sartor O, Vogelzang NJ, Sweeney C, et al. Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. experience from an expanded access program. Oncologist. 2018;23(2):193–202. doi:10.1634/theoncologist.2017-041329183960
   PubMed Web of Science ®Google Scholar
• Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):408–419. doi:10.1016/S1470-2045(18)30860-X30738780
   PubMed Web of Science ®Google Scholar
• Woon DTS, Chandrasekar T, Aaron L, et al. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. Can Urol Assoc J. 2018;12(10):328–336. doi:10.5489/cuaj.537829688882
   PubMed Web of Science ®Google Scholar